论文部分内容阅读
目的 :探讨 p5 3蛋白与肺癌多药耐药 (MDR)的关系。方法 :运用 S- P免疫组化法和反转录 -聚合酶链反应 (RT- PCR)技术 ,对 40例肺癌组织中 p5 3蛋白、多药耐药 (mdr- 1)基因和多药耐药相关蛋白 (mrp)基因表达进行检测。结果 :癌组织 p5 3阳性的 mdr- 1、m rp阳性率高于 p5 3阴性者 (P<0 .0 5 ) ;p5 3和 mdr- 1、m rp阳性率与肺癌的病理分期、组织学类型、分化程度和淋巴结转移无关 (P>0 .0 5 ) ,但它们在低分化肿瘤和淋巴结转移标本的阳性率高于中高分化和无淋巴结转移者。结论 :p5 3蛋白对肺癌细胞的 mdr- 1、mrp表达可能起调控作用 ,促使肺癌细胞 MDR的产生。
Objective: To investigate the relationship between p5 3 protein and multidrug resistance (MDR) in lung cancer. Methods: The expressions of p5 3 protein, multidrug resistance (mdr-1) gene and multidrug resistance in 40 lung cancer tissues were detected by S-P immunohistochemistry and reverse transcriptase-polymerase chain reaction Drug-related protein (mrp) gene expression was detected. Results: The positive rates of mdr-1 and mrp in p5 3 -positive cancers were higher than those in p5-negative ones (P <0.05). The positive rates of p5 3, mdr-1 and mrp were correlated with the pathological stage, histology Type, degree of differentiation and lymph node metastasis (P> 0.05), but their positive rates in poorly differentiated tumors and lymph node metastasis specimens were higher than those in moderately well-differentiated and without lymph node metastases. CONCLUSION: The expression of mdr-1 and mrp in p5 3 protein may play a regulatory role in lung cancer cells and promote the generation of MDR in lung cancer cells.